SCHEMBL5433657

SCHEMBL5433657

Cc1ccc(Cl)cc1-c1noc(-c2ccc(CC(C)C)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 12/20 0.56
NPC1 O15118 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
RAB9A P51151 4/20 0.55
MEN1 O00255 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
KMT2A Q03164 1/20 0.55
S1PR5 Q9H228 6/20 0.49
S1PR4 O95977 5/20 0.49
S1PR3 Q99500 4/20 0.49
NR1H4 Q96RI1 2/20 0.47
MAPT P10636 2/20 0.43
TP53 P04637 2/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739134 0.79 S1PR1 (0.57) S1PR1NPC1SMN1; SMN2RAB9AMEN1
SCHEMBL3456593 0.77 S1PR1 (0.54) S1PR1NPC1SMN1; SMN2RAB9AS1PR5
SCHEMBL5501327 0.77 S1PR1 (0.63) S1PR1NPC1SMN1; SMN2RAB9AMEN1
SCHEMBL4741310 0.75 S1PR1 (0.54) S1PR1S1PR5S1PR4S1PR3
SCHEMBL4744254 0.75 S1PR1 (0.61) S1PR1S1PR5S1PR4S1PR3
SCHEMBL4741601 0.74 S1PR1 (0.52) S1PR1S1PR5S1PR4S1PR3
SCHEMBL5952049 0.74 ACHE (0.57) S1PR1NPC1SMN1; SMN2RAB9AS1PR5
SCHEMBL3457539 0.73 S1PR1 (0.53) S1PR1NPC1SMN1; SMN2RAB9AS1PR5
SCHEMBL16844821 0.73 S1PR1 (0.70) S1PR1NPC1SMN1; SMN2RAB9AMEN1
SCHEMBL16591200 0.73 S1PR1 (0.58) S1PR1S1PR5S1PR4S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043014-A1 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists MERCK & CO., INC. (US) 2007-02-22 US disclosed
EP-1670463-A2 3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS Merck & Co., Inc. (US) 2006-06-21 EP disclosed
WO-2005032465-A2 3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS MERCK & CO., INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043014-A1 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists S1PR3, S1PR1, S1PR5 S1PR1 2/4885NPC1 901/4885SMN1; SMN2 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.